A Special Purpose Acquisition Company (SPAC) is a “blank check” shell company created to raise funds through an IPO to finance a merger or acquisition. In 2020 and 2021, SPAC activity surged dramatically, raising over $83B across 248 IPOs in 2020 and $160B across 613 IPOs in 2021. Healthcare-focused SPACs alone contributed $11.1B in 2020…
Shots: Citius Pharmaceuticals celebrates its first-ever FDA approval with Lymphir, a novel therapy for relapsed or refractory cutaneous T-cell lymphoma In an exclusive conversation, Leonard Mazur, Co-Founder and CEO at Citius Pharmaceuticals, shares insights on Lymphir’s launch strategy and its potential impact on the oncology landscape Leonard also highlights Mino-Lok, Citius’ innovative…
Medical psychedelics are a fascinating field that modern science has yet to comprehend completely. Researchers are still digging up, trying to find evidence-based outcomes to tap into a whole new opportunity in psychiatry and mental health medicinesThe September Edition unearths a brand-new perspective on psychedelics through engaging articles, illustrative infographics, trailing BioTrends, illuminating regulatory…
Last month, we explored four key trends shaping the biopharma industry in 2025. In this follow-up, we spotlight the evolving role of multi-omics analysis—a field rapidly transforming how diseases are understood, diagnosed, and treated.In 2024, the global multi-omics market was valued at $2.72 billion and is projected to reach $9.91 billion by 2033, growing…
Shots: Product recalls in biopharma and MedTech incur an unanticipated drain on budget, costing the industry between $2.5B to $5B per year on average Honeywell’s TrackWise Recall Management helps biopharma and MedTech companies plan and execute recall processes seamlessly, contributing to improved patient safety and faster response times Shawn Opatka, Vice President & General Manager,…
This exclusive breakfast meetup is designed for busy Clinical Trials Operation executives who want to gain high-value insights without committing to a full-day event.For any queries, reach out to Tina Aston at ta@worldbigroup.comRelated Post: Drug Discovery and Innovation Programme 2025 | Sep 25-26 |Barcelona, Spain
Regenerative medicine holds a promising potential in addressing unmet medical needs and bridging the gaps in healthcare. Regenerative medicine aims to provide innovative ways to repair, rejuvenate, and replace damaged tissues and organs. Regenerative medicine is widely explored in clinical settings as cellular therapies, extracellular vesicle therapies, immune cellular therapies, and tissue-engineered grafts to prevent…
Decentralized Clinical Trials (DCTs) colloquially known as hybrid trials were popularized during COVID-19. With the changing healthcare landscape, trial sponsors are looking for practices that are feasible and cost-effective. DCTs offer holistic solutions to mitigate the gaps in traditional clinical trial models by integrating emerging technologies and gadgets into the nuanced aspects of data capturing.…
Automation remained a quintessential force throughout 2024 in shaping the biopharma industry. 2025 on the other hand is experiencing advanced applications of automated tools and enablers in different aspects of drugs life cycles. PharmaShots through this magazine navigates automated packaging by decrypting the complexities of automation. The magazine unfolds the role of automation in biopharma…
Emerging technologies holds a promising foothold in redefining the aspects of preventative, diagnostic, therapeutic, and patient care in the healthcare landscape. 3D Bioprinting offers innovative approach to addressing unmet healthcare needs with efficacious precision medicine in life-threatening conditions and developing therapies and medical devices that mimic complex human physiology. In April, PharmaShots Magazine is exploring…

